Innocrin Pharmaceuticals
2014
FOUNDED
PRIVATE
STATUS
1-10
EMPLOYEES
Accelerator/Inc
LATEST DEAL TYPE
9
INVESTORS
Description
Developer of oral inhibitors designed to treat advanced breast and prostate cancer. The company's oral inhibitors consists of oral CYP17 lyase inhibitors for the treatment of castration-resistant prostate cancer (CRPC) and potentially in other hormonally-driven conditions such as breast cancer, endometriosis or congenital adrenal hyperlplasia.
Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Pharmaceuticals
Other Industries
Biotechnology
Primary Office
- 4505 Emperor Boulevard
- Suite 315
- Durham, NC 27703
- United States
+1 (919) 000-0000
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore Innocrin Pharmaceuticals’s full profile, request a free trial.
Innocrin Pharmaceuticals Valuation and Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Accelerator/Incubator | 0000 | Completed | Generating Revenue | |||
| 1. Later Stage VC (Series D) | 14-Apr-2015 | 0000 | 0000 | Completed | Generating Revenue |
Innocrin Pharmaceuticals Competitors (14)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Amplyx | Venture Capital-Backed | San Diego, CA | 00 | 00000 | 00000000000 | 00000 |
| 000000000 | Formerly VC-backed | Exton, PA | 000 | 0000 | 000000&0 | 0000 |
| 0000000 0000000000 | Formerly VC-backed | Cambridge, MA | 00 | 00000 | 000000000 | 00000 |
| 00 000000000000 | Formerly VC-backed | Durham, NC | 00 | 00000 | 00000000000 | 00000 |
| 0000000 | Private Equity-Backed | San Diego, CA | 000 | 00000 | 0000000 0000 | 00000 |
Innocrin Pharmaceuticals Investors (9)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Board Seat |
Contact Info |
|---|---|---|---|---|---|---|
| A&B Equity Holdings | Other | Minority | 000 0000 | 000000 0 | ||
| Astellas Venture Management | Corporate Venture Capital | Minority | 000 0000 | 000000 0 | ||
| Eshelman Ventures | Venture Capital | Minority | 000 0000 | 000000 0 | ||
| Hatteras Venture Partners | Venture Capital | Minority | 000 0000 | 000000 0 | ||
| Intersouth Partners | Venture Capital | Minority | 000 0000 | 000000 0 |
Innocrin Pharmaceuticals Executive Team (7)
2 Former Executives
You’re viewing 5 of 7 executives. Get the full list »Innocrin Pharmaceuticals Board Members (10)
| Name | Representing | Role | Since | Contact Info |
|---|---|---|---|---|
| Andrew von Eschenbach MD | Self | Board Member | 000 0000 | |
| Douglas Reed MD | Hatteras Venture Partners | Chairman | 000 0000 | |
| Fred Eshelman | Self | Chief Executive Officer & Board Member | 000 0000 | |
| Kristopher Wood | Lurie Holdings | Board Member | 000 0000 | |
| Richard Kent MD | Intersouth Partners | Board Member | 000 0000 |
2 Former Board Members
You’re viewing 5 of 10 board members. Get the full list »